Purple Biotech Announces the Initiation of Phase 2 Study for CM24 in 2L PDAC Patients
18 mai 2022 08h18 HE
|
Purple Biotech Ltd.
REHOVOT, Israel, May 18, 2022 (GLOBE NEWSWIRE) -- Purple Biotech Ltd. ("Purple Biotech", or the "Company") (NASDAQ/TASE: PPBT), a clinical-stage company focused on developing first-in-class,...
Purple Biotech Reports First Quarter 2022 Financial Results
12 mai 2022 08h13 HE
|
Purple Biotech Ltd.
REHOVOT, Israel, May 12, 2022 (GLOBE NEWSWIRE) -- Purple Biotech Ltd. ("Purple Biotech", or the "Company") (NASDAQ/TASE: PPBT), a clinical-stage company developing first-in-class, effective and...
Purple Biotech Presents Positive Interim Phase 1b Study Results for CM24 at the American Association of Cancer Research 2022 Annual Meeting
11 avr. 2022 07h37 HE
|
Purple Biotech Ltd.
First-in-class monoclonal antibody in combination with Opdivo® (nivolumab) demonstrates strong safety and an initial efficacy profile for PDAC REHOVOT, Israel, April 11, 2022 (GLOBE NEWSWIRE)...
Purple Biotech Reports Second Half and Full-Year 2021 Financial Results
09 févr. 2022 07h00 HE
|
Purple Biotech Ltd.
REHOVOT, Israel, Feb. 09, 2022 (GLOBE NEWSWIRE) -- Purple Biotech Ltd. ("Purple Biotech", or the "Company") (NASDAQ/TASE: PPBT), a clinical-stage company developing first-in-class, effective and...
Purple Biotech Issues Letter to Shareholders
04 févr. 2022 07h35 HE
|
Purple Biotech Ltd.
REHOVOT, Israel, Feb. 04, 2022 (GLOBE NEWSWIRE) -- Purple Biotech Ltd. ("Purple Biotech", or the "Company") (NASDAQ/TASE: PPBT), a clinical-stage company developing first-in-class, effective and...
Purple Biotech Appoints Life Sciences Industry Investor Ori Hershkovitz to its Board of Directors
06 janv. 2022 07h30 HE
|
Purple Biotech Ltd.
REHOVOT, Israel, Jan. 06, 2022 (GLOBE NEWSWIRE) -- Purple Biotech Ltd. ("Purple Biotech", or the "Company") (NASDAQ/TASE: PPBT), a clinical-stage company developing first-in-class, effective and...
Purple Biotech Appoints Senior Business Development Executive Fabien Sebille as Chief Business Officer
09 déc. 2021 07h30 HE
|
Purple Biotech Ltd.
REHOVOT, Israel, Dec. 09, 2021 (GLOBE NEWSWIRE) -- Purple Biotech Ltd. ("Purple Biotech", or the "Company") (NASDAQ/TASE: PPBT), a clinical-stage company developing first-in-class, effective and...
Purple Biotech Announces Initiation of Part 2 of Ongoing Phase 1/2 Clinical Trial Evaluating NT219 for Treatment of Multiple Cancers Supporting Potential Expansion of Clinical Program
06 déc. 2021 07h30 HE
|
Purple Biotech Ltd.
Part 2 is a Dose Escalation Study of NT219, in Combination with cetuximab (ERBITUX®), in Patients with Recurrent and/or Metastatic Squamous Cell Carcinoma of Head and Neck Cancer or Colorectal...
Purple Biotech to Present at the Jefferies London Healthcare Conference
03 nov. 2021 07h30 HE
|
Purple Biotech Ltd.
REHOVOT, Israel, Nov. 03, 2021 (GLOBE NEWSWIRE) -- Purple Biotech Ltd. ("Purple Biotech" ", or the "Company") (NASDAQ/TASE: PPBT), a clinical-stage company developing first-in-class, effective and...
Purple Biotech Expands Research Collaboration in Immuno-Oncology in Combination with NT219
26 oct. 2021 08h27 HE
|
Purple Biotech Ltd.
Collaboration to Study NT219 in Combination with anti-CTLA4 and anti-PD1/PDL1 Antibodies REHOVOT, Israel, Oct. 26, 2021 (GLOBE NEWSWIRE) -- Purple Biotech Ltd. ("Purple Biotech", or the...